Tabular list notes for Z79.810
The tabular list has no notes on Z79.810 itself; the notes below apply from its parent headings.
Inherited from Z79 (Long term (current) drug therapy)
- Includes
- long term (current) drug use for prophylactic purposes
- Excludes2 (not part of this condition, may be coded together)
- drug abuse and dependence (F11-F19)
- drug use complicating pregnancy, childbirth, and the puerperium (O99.32-)
- Code also
- any therapeutic drug level monitoring (Z51.81)
Inherited from Z79.81 (Long term (current) use of agents affecting estrogen receptors and estrogen levels)
- Excludes1 (never coded together)
- hormone replacement therapy (Z79.890)
- Code first
- , if applicable:
- malignant neoplasm of breast (C50.-)
- malignant neoplasm of prostate (C61)
- Use additional code
- code, if applicable, to identify:
- estrogen receptor positive status (Z17.0)
- family history of breast cancer (Z80.3)
- genetic susceptibility to malignant neoplasm (cancer) (Z15.0-)
- personal history of breast cancer (Z85.3)
- personal history of prostate cancer (Z85.46)
- postmenopausal status (Z78.0)
MS-DRG grouping when Z79.810 is the principal diagnosis
| MDC | MS-DRGs |
|---|---|
| 23 MDC 23: Factors Influencing Health Status and Other Contacts with Health Services | 951 |
The final group also depends on procedures, secondary diagnoses and discharge status; the MS-DRG lookup for Z79.810 shows the full grouping logic.
CC/MCC status and inpatient edits
Z79.810 is neither a CC nor an MCC under MS-DRG v44, so as a secondary diagnosis it does not raise the MS-DRG severity level. Check Z79.810 against a principal diagnosis.
- Present on admission: exempt from POA indicator reporting (FY2027 exempt list).
- Medicare Code Editor: unacceptable principal diagnosis.
CMS-HCC V28 risk adjustment
Z79.810 does not map to a payment HCC in the PY2027 CMS-HCC V28 model, so on its own it does not change a Medicare Advantage risk score.
LCD billing and coding articles that list Z79.810
6 current Medicare billing and coding articles list Z79.810 among the diagnoses that support medical necessity for the services they cover.
- Billing and Coding: Bevacizumab and biosimilars A52370
- Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars A52399
- Billing and Coding: Bisphosphonate Drug Therapy A56907
- Billing and Coding: Vitamin D Assay Testing A57718
- Billing and Coding: Vitamin D Assay Testing A57736
- Billing and Coding: Vitamin D Assay Testing A59170
For teams evaluating QuickIntell software
Evaluate software for diagnosis coding review
If your team codes diagnoses at volume, review how QuickCode supports qualified coder review of documentation, specificity queries and the billing handoff. Confirm the code sets, settings and reviewer responsibilities during evaluation; a code reference is not a coding determination for a patient.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does ICD-10-CM Z79.810 mean?
Z79.810 means long term (current) use of selective estrogen receptor modulators (SERMs). It is one of 25 billable codes under Z79, long term (current) drug therapy.
What can't be coded with Z79.810?
Excludes1 at Z79.81: hormone replacement therapy (Z79.890). These are never reported together with Z79.810.
Which MS-DRG does Z79.810 group to?
As the principal diagnosis, Z79.810 groups to MS-DRG 951 Other Factors Influencing Health Status (MDC 23 MDC 23: Factors Influencing Health Status and Other Contacts with Health Services) under MS-DRG v44, before procedures and secondary diagnoses are applied.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-10. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- ICD-10-CM FY2027 tabular order file (category titles)Version FY2027 · effective 2026-10-01 · file icd10cm_order_2027.txtSHA-256 38981fb2c1226e2b…
- ICD-10-CM FY2027 tabular list (chapter titles and ranges)Version FY2027 · effective 2026-10-01 · file 2027-code-tables-tabular-index.zipSHA-256 37baa476323714be…
- ICD-10-CM FY2027 code descriptions addenda (codes added, deleted and revised)Version FY2027 · effective 2026-10-01 · file icd10cm_codes_addenda_2027.txtSHA-256 cfba025073235af4…
- ICD-10 MS-DRG Definitions Manual v44 (text)Version v44 · effective 2026-10-01 · file fy2027-fr-icd10-ms-drg-definitions-manual-files-v44.zipSHA-256 ae4f6c11727fe91f…
- IPPS FY2027 Tables 6A-6K: new, invalid and revised ICD-10-CM/PCS codes, CC/MCC list changes and CC exclusionsVersion FY2027 (final rule; not reissued by CN3) · effective 2026-10-01 · file fy2027-ipps-fr-tables-6a-6k.zipSHA-256 ca0af87b0869a405…
- ICD-10-CM FY2027 POA-exempt codes (full list, additions, deletions and revisions)Version FY2027 · effective 2026-10-01 · file 2027-poa-exempt-codes.zipSHA-256 03f55091045024d0…
- ICD-10-CM to CMS-HCC V28 mappings, payment year 2027 initialVersion PY2027 initial ICD-10-CM mappings (dates of service 2026) · effective 2027-01-01 · file 2027 Initial ICD-10-CM Mappings.csvSHA-256 9c260b06d0dd2806…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-10-08 · effective 2026-10-04 · file article.csvSHA-256 5e95c4a8ac3664be…
Disclaimer
The descriptor and notes are reproduced from the FY2027 ICD-10-CM files; MS-DRG, CC/MCC and HCC facts come from the CMS FY2027 and PY2027 tables. Code from the medical record and the ICD-10-CM Official Guidelines. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.